Financial Snapshot
Revenues
Revenues
Revenue YoY Change
Revenues
Expenses
Cost Of Revenues
Gross Profit
Gross Profit Margin
Gross Profit
Selling, General & Admin Expense
Research & Development
Depreciation, Depletion & Amortization
SGA Expense to Gross Profit Ratio
R&D To Gross Profit Ratio
DDA To Gross Profit Ratio
Operating Expenses Total
Operating Profits/Loss
Operational Expenses
Interest Expenses
Interest Expenses To Operating Income %
Other Expense/Income
Interest & Other Expense/Income
Income/Loss
Pretax Income
Income Tax
Net Profits/Loss
Pretax Income YoY Change
Income Tax Rate
Net Profits/Loss YoY Change
Basic EPS
Net Income To Revenue Ratio
Pretax & Net Income
Assets & Liabilities
Cash & Short-Term Investments
Cash & Equivalents
Cash To Operating Expenses Ratio
Inventory
Receivables
Total Short-Term Assets
Property, Plant And Equipment
Long-Term Investments
Total Long-Term Assets
Total Assets
Net Income To Total Assets Percentage
Accounts Payable
Short-Term Debt
Long Term Debt Due
Total Short-Term Liabilities
Long-Term Debt
Other Long-Term Liabilities
Total Long-Term Liabilities
Total Liabilities
Short-Term To Long-Term Debt Ratio
Short-Term Assets To Debt Ratio
Long-Term Debt To Net Income Ratio
Assets & Liabilities
Ownership
Basic Shares Outstanding
Diluted Shares Outstanding
Preferred Stock
Treasury Stock Shares
Stock Issuance & Repurchase
Ownership Data
Return On Shareholders' Equity
Book Value
Free Cash Flow
Free Cash Flow YoY
Free Cash Flow Margin
Dividends
Dividends
Stock Price
About ChemoCentryx, Inc.
ChemoCentryx, Inc. is a biopharmaceutical company, which engages in the development and commercialization of medicines. The company is headquartered in San Carlos, California and currently employs 178 full-time employees. The company went IPO on 2012-02-08. The firm is targeting the chemokine and chemoattractant systems to discover, develop and commercialize orally-administered therapies. Its development pipelines include TAVNEOS and Immuno-Oncology. TAVNEOS is for the treatment of severe hidradenitis suppurativa (HS) and seeks to advance TAVNEOS into Phase III clinical development for the treatment of severe HS. The firm's CCX559 is orally-administered investigational inhibitor for programmed death protein 1/programmed death-ligand 1 (PD-1/PD-L1), which is developing for the treatment of various cancers. The company markets TAVNEOS (avacopan) as an adjunctive treatment for adult patients with severe active anti-neutrophil cytoplasmic autoantibody-associated vasculitis associated vasculitis, specifically granulomatosis with polyangiitis and microscopic polyangiitis.
Industry: Pharmaceutical Preparations Peers: ARROWHEAD PHARMACEUTICALS, INC. Beam Therapeutics Inc. Blueprint Medicines Corp Denali Therapeutics Inc. Intellia Therapeutics, Inc. Natera, Inc. Mirati Therapeutics, Inc. PTC THERAPEUTICS, INC.
